(NASDAQ: VYGR) Voyager Therapeutics's forecast annual revenue growth rate of -29.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.51%.
Voyager Therapeutics's revenue in 2023 is $158,397,000.On average, 4 Wall Street analysts forecast VYGR's revenue for 2023 to be $6,127,542,173, with the lowest VYGR revenue forecast at $2,991,684,684, and the highest VYGR revenue forecast at $7,241,636,750. On average, 3 Wall Street analysts forecast VYGR's revenue for 2024 to be $2,579,580,119, with the lowest VYGR revenue forecast at $351,962,904, and the highest VYGR revenue forecast at $4,487,527,026.
In 2025, VYGR is forecast to generate $4,567,158,633 in revenue, with the lowest revenue forecast at $4,567,158,633 and the highest revenue forecast at $4,567,158,633.